Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

Background:

Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in the treatment schedule, thus non-responders are subjected to unnecessary toxicity. The potential of circulating microRNAs as early biomarkers of docetaxel response in CRPC patients was investigated in this study.

Methods:

Global microRNA profiling was performed on docetaxel-resistant and sensitive cell lines to identify candidate circulating microRNA biomarkers. Custom Taqman Array MicroRNA cards were used to measure the levels of 46 candidate microRNAs in plasma/serum samples, collected before and after docetaxel treatment, from 97 CRPC patients.

Results:

Fourteen microRNAs were associated with serum prostate-specific antigen (PSA) response or overall survival, according to Mann–Whitney U or log-rank tests. Non-responders to docetaxel and patients with shorter survival generally had high pre-docetaxel levels of miR-200 family members or decreased/unchanged post-docetaxel levels of miR-17 family members. Multivariate Cox regression with bootstrapping validation showed that pre-docetaxel miR-200b levels, post-docetaxel change in miR-20a levels, pre-docetaxel haemoglobin levels and visceral metastasis were independent predictors of overall survival when modelled together.

Conclusions:

Our study suggests that circulating microRNAs are potential early predictors of docetaxel chemotherapy outcome, and warrant further investigation in clinical trials.

Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene

Dysregulation of the PI3K/Akt/mTOR pathway is one of the most frequent events in human cancer. However, the clinical benefits of PI3K/Akt/mTOR inhibitors have not yet achieved their predicted potential in many of the most prevalent human cancers. Of interest, treatment of Kaposi's sarcoma (KS) patients with rapamycin provided the first evidence of the antineoplastic activity of mTOR inhibitors in humans, becoming the standard of care for KS arising in renal transplant patients. Thus, the study of KS may provide a unique opportunity to dissect the contribution of specific mTOR downstream targets to cancer development. The KS-associated herpesvirus (KSHV) is the etiological agent for KS, and the KSHV-encoded oncogene viral-G protein-coupled receptor (vGPCR) promotes the potent activation of the PI3K-Akt-mTOR pathway by both direct and paracrine mechanisms. We focused on a direct target of mTOR, EIF4EBP1/2/3 (4EBP), which inhibits the translation of eukaryotic initiation factor 4E (eiF4E)-bound mRNAs. 4EBP phosphorylation by mTOR relieves its inhibitory activity, hence resulting in increased eiF4E-dependent mRNA translation. We developed a paracrine transformation model, recapitulating the cellular composition of KS lesions, in which vGPCR-expressing cells promote the rapid proliferation of endothelial cells, thus expressing KSHV-latent genes by the release of growth factors. Using this model, we show here that the accumulation of dephosphorylated 4EBP in response to rapamycin or by the expression of an mTOR-insensitive mutant of 4EBP1 is sufficient to disrupt the eiF4E function downstream of mTOR to a similar extent than the mTOR catalytic inhibitor Torin2 and to halt KS development. We also provide evidence that eiF4E contributes to paracrine neoplastic, signaling through the release of pro-angiogenic factors that are acting on endothelial cells, expressing KSHV-latent genes. These findings may provide a preclinical platform and the rationale for the development of novel mTOR, inhibiting agents that may selectively disrupt the mTOR-4EBP interaction for the treatment of KS and other tumor lesions, exhibiting hyperactive mTOR pathway function.

Device Analysis of Cu(In,Ga)Se2 Heterojunction Solar Cells - Some Open Questions

The paper discusses the electronic properties of Cu(In,Ga)Se2–based heterojunction solar cells with a special focus on questions which at present are not satisfactorily understood. First, we discuss an apparent quantitative contradiction between measured concentrations of recombination centers in the Cu(In,Ga)Se2 absorber material and the actual recombination rate in the solar cells. We propose, as a possible explanation for that observation, that the defect concentration in Cu(In,Ga)Se2 is spatially inhomogeneous with a systematic increase towards the heterojunction interface. Second, we address the issue of electronic metastabilities in ZnO/CdS/Cu(In,Ga)Se2 heterojunctions and, especially, in devices that use alternative buffer materials instead of CdS. Starting from a brief review of the experimentally observed types of metastabilities, we demonstrate by thermally stimulated capacitance measurements that a specific type of metastability that severely limits the performance of solar cells with non-CdS buffers is present also in high-efficiency standard devices though it has virtually no influence on the output parameters in the latter case. A possible explanation of this type of metastability points to a metastable defect reaction localized in the close to surface region of Cu(In,Ga)Se2. At the moment we cannot propose conclusive models for both open questions. However, we can localize the answers to both problems in the close-to-surface region of the Cu(In,Ga)Se2 absorber.

Modification of Cu(In, Ga)Se2 Surface by Treatment in Cadmium Solutions

This article investigates chemical modifications of Cu(In, Ga)Se2 thin film by treatment in cadmium solutions with varying [NH3] concentration. Secondary ions mass spectroscopy and Xray photoelectron-spectroscopy analysis show that Cd-diffusion into the Cu(In, Ga)Se2 film is intimately tied to the reduction-oxidation of the Cu(In, Ga)Se2 surface, which is controlled by the [NH3] concentration. Reaction products, like Se and metal hydroxides of the redox process as wellas thediffusedCdinCu(In, Ga)Se2 film, result in degradation of solar cell performance.